Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NLX-101 by Neurolixis for Fragile X Syndrome: Likelihood of Approval
NLX-101 is under clinical development by Neurolixis and currently in Phase I for Fragile X Syndrome. According to GlobalData, Phase...